Core Insights - Exact Sciences Corp. is reinforcing its leadership in breast cancer diagnostics with a strong presence at the 2025 San Antonio Breast Cancer Symposium, presenting 10 abstracts from its Precision Oncology portfolio [1][2][3] Group 1: Oncodetect Test - The Oncodetect test will be clinically validated for triple-negative breast cancer (TNBC), showcasing its high sensitivity in detecting molecular residual disease (MRD) [1][4] - A sub-study in collaboration with the National Surgical Adjuvant Breast and Bowel Project (NSABP) demonstrated the strong predictive performance of the Oncodetect test in patients with early TNBC undergoing neoadjuvant chemotherapy [4][6] Group 2: Oncotype DX Test - The Oncotype DX test is recognized as a global standard for predicting and prognosing breast cancer, aiding clinicians in therapy decisions that improve outcomes and reduce disparities [3][7] - A study confirmed that the Oncotype DX Breast Recurrence Score test can lead to improved outcomes and reduced costs across diverse racial and ethnic subgroups in the US, promoting equitable breast cancer care [7][8] Group 3: Real-World Data and Economic Impact - Real-world data analysis indicates an increasing trend in the adoption of molecular residual disease testing in breast cancer, highlighting its integration into clinical practice [6][8] - The use of the Oncotype DX test in Ireland has resulted in estimated cost savings of over 60 million euros associated with chemotherapy use over an 11-year period [11] Group 4: International Studies - A large-scale study in Japan confirmed appropriate application of the Oncotype DX test in HR+/HER2 early breast cancer, consistent with current guidelines [9] - A prospective evaluation in Switzerland found that the Oncotype DX test significantly influenced adjuvant treatment decisions, particularly in driving chemotherapy de-escalation [10]